Inspire Medical Systems EU
Inspire Medical Systems, Inc. (NYSE: INSP) develops and commercializes the FDA-approved Inspire hypoglossal nerve stimulation implant for obstructive sleep apnea patients intolerant of CPAP, selling directly to US and European hospitals and ambulatory surgery centers.
- Company typePublic
- Founded2007
- Headquarters—
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Inspire Medical Systems EU does
Inspire Medical Systems, Inc. is a publicly traded medical device company (NYSE: INSP) founded in 2007 that develops and commercializes the Inspire hypoglossal nerve stimulation (HNS) implant system for the treatment of obstructive sleep apnea (OSA). The core therapy delivers gentle stimulation to the hypoglossal nerve during sleep to maintain upper-airway patency, and is positioned as a mask-free alternative for adult patients with moderate-to-severe OSA (AHI 15-100) who cannot tolerate or benefit from CPAP therapy. FDA approval was obtained in 2014, supported by the STAR clinical trial, with five-year outcomes subsequently published and a label extension covering pediatric patients aged 13-18 with Down Syndrome and severe OSA (AHI 10-50).
The company's product platform comprises multiple implant generations (Inspire IV, Inspire V, and Models 3024/3028 generators) coupled with the SleepSync connected-care ecosystem, which includes a Bluetooth-enabled patient remote, a mobile app, a web portal, and the SleepSync Programming System (model 2740S) for clinicians. Supporting infrastructure includes the Inspire Institute training platform (powered by 360learning), the Excellence Program for high-performing providers, and the Payer Access Library for reimbursement navigation.
Inspire Medical Systems generates revenue primarily through one-time hospital and ASC device sales, supplemented by physician professional services and ongoing sleep services billed under CPT codes, including remote therapeutic monitoring codes enabled by the SleepSync platform. The company employs a direct enterprise field-sales motion targeting ENT surgeons and sleep medicine physicians, supported by in-house prior authorization and reimbursement teams. Commercial operations span the United States — where Inspire therapy is covered by Medicare, broad private insurance, and many VA and military hospitals — and Europe, anchored by a Hamburg-based subsidiary and historical STAR trial enrollment at 22 US and European medical centers.
Inspire Medical Systems EU firmographics
Firmographics- Name
- Inspire Medical Systems EU
- Legal name
- Inspire Medical Systems, Inc.
- Website
- https://professionals.inspiresleep.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Inspire Medical Systems, Inc. (NYSE: INSP) develops and commercializes the FDA-approved Inspire hypoglossal nerve stimulation implant for obstructive sleep apnea patients intolerant of CPAP, selling directly to US and European hospitals and ambulatory surgery centers.
- Ownership category
- akta.pro rank
Inspire Medical Systems EU industry classification
Industry- Product category
- Neurostimulation medical devices for sleep apnea
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV) (HLAHAGAA)
Keywords
Inspire Medical Systems EU business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Others
Revenue model
- Inspire Implant Device Sales: One-time device sales of the Inspire implant system to hospitals and ambulatory surgery centers (ASCs). The system is billed using CPT procedure codes and hospital device codes. Covers Inspire V and Inspire IV system generations.
- Physician/Surgical Procedure Billing: Physician services for implant procedure billed using CPT codes. Includes post-implant care, follow-up appointments, and sleep study titrations. Remote therapeutic monitoring (RTM) codes available for ongoing patient monitoring.
- Sleep Services and Programming: Ongoing sleep services including implant activation, therapy adjustments, and system checks billed through CPT codes. Remote monitoring through SleepSync platform eligible for Category 1 CPT codes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Insurance/Reimbursement-based pricing |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Inspire Medical Systems EU product offering
Product offeringCore offering
Inspire Medical Systems EU markets the Inspire Upper Airway Stimulation system, an FDA-approved hypoglossal nerve stimulation implant that treats moderate-to-severe obstructive sleep apnea in CPAP-intolerant adult patients and in pediatric Down Syndrome patients. The offering comprises the implantable neurostimulator (Models 3024 and 3028) with sensing and stimulation leads, the SleepSync Programming System (2740S) for clinicians, the SleepSync Patient Management Platform with a Bluetooth-enabled Inspire Remote and Inspire app, plus the Inspire Institute training platform and Payer Access Library. The product is sold directly to hospitals and ambulatory surgery centers through a field sales model with in-house reimbursement support.
Product overview
Inspire Medical Systems EU offers a unified medical device ecosystem for treating obstructive sleep apnea (OSA) through upper airway stimulation. The core offering is the Inspire implant system (Models 3024 and 3028), which is complemented by the SleepSync Patient Management Platform comprising the Bluetooth-enabled Inspire Remote, Inspire App, and SleepSync Programming System (2740S) software. Supporting infrastructure includes the Inspire Excellence Program for provider recognition, Inspire Institute for clinician training via 360learning, and the Payer Access Library for insurance coverage guidance. Together, these products enable mask-free OSA treatment with remote monitoring capabilities and wireless data synchronization across patient and clinical interfaces.
Differentiator
Problem solved
Functional benefit
Brands
- SleepSync™: Connected patient management platform consisting of Bluetooth-enabled Inspire remote, Inspire app, and SleepSync web portal for wireless implant monitoring and care coordination.
- Inspire Institute
Products and services
- Inspire Therapy (Upper Airway Stimulation System) FDA-approved implantable neurostimulator system (Models 3024 and 3028) that delivers gentle stimulation to the hypoglossal nerve during sleep to keep the airway open, for adults with moderate to severe OSA (AHI 15-100) who are CPAP-intolerant and for pediatric Down Syndrome patients with severe OSA (AHI 10-50). Sold to hospitals and ambulatory surgery centers and implanted by Inspire-trained ENT and sleep medicine physicians.
- SleepSync Programming System (Model 2740S)
Quantifiable outcome
- 79% reduction in AHI events (sleep apnea events)
- +6 more outcomes
Companies that use Inspire Medical Systems EU
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Inspire Medical Systems EU technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Inspire Medical Systems EU partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Inspire Medical Systems EU competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Largest implantable neurostimulator maker, with established cranial and peripheral nerve stimulation franchises. Comparable as a broad incumbent with the scale, manufacturing, and hospital relationships that any large-scale implant competitor (or partner) would need to leverage.
- Fisher & Paykel Healthcare: New Zealand-listed respiratory care company with strong CPAP and OSA-adjacent product lines. Comparable as a peer in the broader OSA therapy market, though it does not offer an implantable neurostimulation alternative.
- ZOLL Itamar Medical: Sleep diagnostics franchise (WatchPAT) focused on home sleep apnea testing and OSA diagnosis. Comparable as an ecosystem peer in the OSA care pathway, addressing diagnosis rather than treatment, but often co-marketed alongside OSA therapy decisions.
- Philips Respironics: Major CPAP and sleep-respiratory care franchise from Philips. Comparable as a directly competing OSA therapy provider, though currently scaled back from CPAP following its 2021 recall and ongoing remediation.
- LivaNova: Global neuromodulation company with implantable stimulation devices for epilepsy and depression. Comparable because of its deep expertise in implantable neurostimulator design, regulatory pathways, and payer engagement — relevant infrastructure for any OSA neuromodulation entrant.
- ResMed: Global leader in CPAP devices and broader sleep-disordered breathing care. Comparable because it serves the same OSA patient pool that Inspire targets, but with the incumbent first-line therapy (CPAP) rather than a surgical implant.
Emerging players
- Somnics: Developer of iNAP, a sleep-position and oral-pressure OSA therapy. Comparable because it offers a non-CPAP alternative for OSA patients, though via a completely different mechanism (negative intraoral pressure) rather than hypoglossal nerve stimulation.
- ApniMed: Clinical-stage company developing pharmacologic (oral) treatments for OSA. Comparable because it is targeting the same moderate-to-severe OSA patient pool that Inspire addresses, but with a non-surgical, non-device therapeutic approach.
Direct peers
- Nyxoah: Belgium-based developer of a hypoglossal nerve stimulation implant (Genio) for CPAP-intolerant OSA patients. Comparable because it targets the identical patient population with a similar neuromodulation mechanism, differing primarily in leadless design and EU-first commercialization.
Regional players
- BMC Medical: China-based manufacturer of CPAP and respiratory care devices. Comparable as a CPAP-side competitor in the broader OSA therapy market, primarily serving the APAC region rather than competing head-on with Inspire in the US or EU.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Inspire Medical Systems EU social profiles
Digital presenceInspire Medical Systems EU compliance and trust
Trust signalCompliance1 record
Inspire Medical Systems EU financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inspire Medical Systems EU leadership team
Management profileNumber of profiles
Profiles5 records
Inspire Medical Systems EU funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inspire Medical Systems EU M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inspire Medical Systems EU
What does Inspire Medical Systems EU do?
Inspire Medical Systems EU markets the Inspire Upper Airway Stimulation system, an FDA-approved hypoglossal nerve stimulation implant that treats moderate-to-severe obstructive sleep apnea in CPAP-intolerant adult patients and in pediatric Down Syndrome patients. The offering comprises the implantable neurostimulator (Models 3024 and 3028) with sensing and stimulation leads, the SleepSync Programming System (2740S) for clinicians, the SleepSync Patient Management Platform with a Bluetooth-enabled Inspire Remote and Inspire app, plus the Inspire Institute training platform and Payer Access Library. The product is sold directly to hospitals and ambulatory surgery centers through a field sales model with in-house reimbursement support.
Is Inspire Medical Systems EU a public or private company?
Inspire Medical Systems EU is a public company. It is classified as public and is currently operating.
When was Inspire Medical Systems EU founded?
Inspire Medical Systems EU was founded in 2007. It employs 11 to 50 people.
How does Inspire Medical Systems EU make money?
Three revenue lines are on record. Inspire Implant Device Sales are the primary driver. The others are physician/Surgical Procedure Billing and sleep Services and Programming.
Who are Inspire Medical Systems EU's main competitors?
Broad incumbents on record are Medtronic, Fisher & Paykel Healthcare, ZOLL Itamar Medical, Philips Respironics, LivaNova and ResMed. Emerging players are Somnics and ApniMed. Nyxoah is listed as a direct peer. BMC Medical is listed as a regional player.
Does Inspire Medical Systems EU have an API?
No public API is recorded for Inspire Medical Systems EU.
What industry is Inspire Medical Systems EU in?
Inspire Medical Systems EU's product category is Neurostimulation medical devices for sleep apnea. Its primary akta.pro industry code is HLAHAGAA, Sleep Apnea Therapy Devices (CPAP/APAP/BiPAP/ASV). Its NAICS code is 334510 and its SIC code is 3845.